Compare CLMB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | DCTH |
|---|---|---|
| Founded | 1982 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 578.4M |
| IPO Year | 1996 | 2015 |
| Metric | CLMB | DCTH |
|---|---|---|
| Price | $32.97 | $14.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $32.33 | $24.00 |
| AVG Volume (30 Days) | 128.4K | ★ 253.4K |
| Earning Date | 10-28-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | 14.29 | ★ 107.53 |
| EPS | ★ 0.48 | 0.04 |
| Revenue | ★ $652,517,000.00 | N/A |
| Revenue This Year | $12.32 | $24.61 |
| Revenue Next Year | $9.32 | $24.27 |
| P/E Ratio | ★ $68.30 | $360.50 |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $8.12 |
| 52 Week High | $79.12 | $17.42 |
| Indicator | CLMB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 41.02 |
| Support Level | $28.65 | $14.00 |
| Resistance Level | $34.14 | $16.51 |
| Average True Range (ATR) | 1.05 | 0.49 |
| MACD | -0.19 | -0.05 |
| Stochastic Oscillator | 66.52 | 26.92 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.